
Indivior reaches settlement with Mylan over patent dispute
pharmafile | September 25, 2017 | News story | Sales and Marketing | Mylan, indivior, patent, pharma, pharmaceutical, suboxone
Indivior has ended a patent dispute with Mylan concerning its heroin addiction therapy Suboxone (buprenorphine and naloxone) sublingual film by agreeing to an undisclosed settlement with the company.
Suboxone is Indivior’s best-selling product, responsible for 90% of its total revenue. The company launched legal action on 15 September over patent infringement allegations against Actavis, Teva, Alvogen and Par after the US District Court for Delaware ruled two weeks before that a generic version of Suboxone developed by Dr Reddy’s did not breach its patents.
The development hit Indivior hard, wiping away £1 billion of its value. It is estimated that generic competition to Suboxone could threaten up to 80% of the drug’s market share, meaning its manufacturer could face big problems in the near future as rival treatments close in.
“We are pleased to have amicably settled all outstanding litigation with Mylan,” commented Shaun Thaxter, CEO of Indivior. “The agreement at once reflects our desire to create further certainty for Indivior and underscores the strength of our intellectual property. Further, as recently demonstrated with our newly granted ‘454 patent, we expect to expand the intellectual property estate for Suboxone film and vigorously assert and defend it.”
The two companies will now submit the settlement for review by the US Federal Trade Commission and the US Justice Department.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






